https://www.selleckchem.com/products/nd-630.html
Currently, children at the highest risk for CVC-related VTE are not well represented in the published pediatric DOAC trials.Introduction Monoclonal antibodies (MoAbs) are rapidly changing the therapeutic scenario of multiple myeloma. Most of the available data, however, come from studies performed in patients with relapsed or refractory disease.Area covered Here, the most recent results from clinical trials that have investigated (or are investigating) efficacy and safety of MoAbs as front-line treatments in both transplant-eligible and
Like
Comment
Share
